Ophthalmic medical technology company commercializing adjustable intraocular lenses and light delivery systems for cataract surgery.
Profile & Fundamentals
Review the profile, reported financial history, AI financial assessment, dividends, splits, and dated events for RxSight.
Profile & Fundamentals
RxSight Profile & Fundamentals
Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.
Explore this pageJump to a Profile & Fundamentals section
Explore this research
Profile & Fundamentals contents
Jump directly to any section
Company and Market Context
Company Profile & Ownership
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is headquartered in Aliso Viejo, California.
Company profile record
Rxsight Inc
Common Stock · Healthcare · Medical Devices
Company
- Company / asset
- Rxsight Inc
- Security type
- Common Stock
- Sector
- Healthcare
- Industry
- Medical Devices
- HQ
- 🇺🇸 United States
- Head office
- 100 Columbia, Aliso Viejo, CA, United States, 92656
Leadership & scale
- Chief executive
- Dr. Ronald M. Kurtz M.D.
- CEO year born
- 1963
- Full-time employees
- 461
- Fiscal year end
- December
- IPO date
- 2021-07-30
Fundamentals snapshot
- Market Cap
- USD 248.2M
- P/E
- --
- Revenue (Q1 26)
- USD 30.9M
- Profit (Q1 26)
- USD -15.9M
- Dividend Yield
- --
- Revenue (FY 25)
- USD 134.5M
- Shares in public float
- 39.1M
- Insider ownership
- 6.45%
Reporting & identifiers
- Symbol
- RXST.NASDAQ
- Listing
- 🇺🇸 United States | Dividend Tax: 30%
- Ticker Currency
- USD
- Income Statement Currency
- USD
- Balance Sheet Currency
- USD
- Cash Flow Currency
- USD
- EPS Currency
- USD
- Contract Type
- SPOT
- ISIN
- US78349D1072
- Asset ID
- equity_73ac566d-3909-558b-b1ed-6b4754a19ed8
Ownership
Shares Outstanding
Latest: 41.3M | Max: 41.3M | Min: 19.1M
Complete Research Workspace
Unlock the complete Profile & Fundamentals
Sign in to verify your access, or upgrade to the Base plan to open every chart, financial statement, event, and source table.